Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.6.3.1 (Mg2+-ATPase)
 1,484 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The activity of two membrane-bound enzymes of human platelets subjected to DMSO and a freezing-thawing process were analysed. Following treatment of fresh platelets with DMSO (5-20%) quantitative differences of AChE and 'ecto-ATPase' activities were seen. After cryopreservation of platelets in 5% DMSO the enzymatic activities of AChE and Mg2+-ATPase were no different from those obtained for fresh platelets. The lack of any changes in the activities of the enzymes of frozen platelets subjected to a washing procedure to remove DMSO, indicates that the mechanism of the DMSO-induced effect is reversible and that freezing-thawing process had no additional detrimental effects.
 ...
PMID:Effect of DMSO and a freezing-thawing process on the 'ecto-ATPase' and AChE activities of human platelets. 294 81

The effect of a new phosphorothionate, the ethyl ester of 2-butenoic acid 3-diethoxy phosphinothioyl (RPR-V) synthesized at the Indian Institute of Chemical Technology, Hyderabad was studied using peroral doses of 0.033, 0.066 and 0.099 mg kg(-1) in male and female rats daily over 90 days. This repeated administration of RPR-V caused significant inhibition of acetylcholinesterase, Na+-K+, Mg2+ and Ca2+-ATPases in the brain of male and female rats when measured after 45 and 90 days of treatment. The effects of the low dose were generally not statistically significant, whereas medium and high doses caused significant effects. Females were more susceptible with regard to brain AChE, but the reverse was seen with Mg2+-ATPase, suggesting sexual dimorphism. Enzyme recoveries were seen 28 days after the final dose. Since RPR-V not only inhibited AChE but also ATPases, it is possible that both synaptic transmission and nerve conduction were affected.
 ...
PMID:Effects of a new phosphorothionate (RPR-V) on ATPases and acetylcholinesterase in rat brain by subchronic dosing. 933 39